Herriot Tabuteau, Chief Executive Officer of Axsome Therapeutics, Inc. (AXSM), sold 49,666 shares of the company's stock on July 1, 2026. The transaction, executed at a price of $240.25 per share, amounted to approximately $11.93 million.
This sale by a key executive represents a significant divestment. Insider sales can be motivated by a variety of personal financial decisions, such as portfolio diversification or tax planning, and do not necessarily indicate a change in the insider's confidence in the company's future prospects.
The filing shows other recent sales by Axsome Therapeutics insiders, including transactions by Roger Jeffs, Mark Coleman, and Susan Mahony in June 2026.